Today announced the forthcoming presentations of data highlighting pacritinib.

Acute Myeloid Leukemia: Clinical Studies: Poster III Abstract #3690.. CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting CTI BioPharma Corp. today announced the forthcoming presentations of data highlighting pacritinib, an oral multikinase inhibitor with dual activity against FLT3 and JAK2, and tosedostat, an oral selective inhibitor of aminopeptidases, at the 56th American Society of Hematology Annual Meeting and Exposition, becoming held December 6-9 in SAN FRANCISCO BAY AREA, CA. The presentations includes data on the experience of pacritinib in stroma adherent severe myeloid leukemia cells, a profile of kinase inhibition across several cell signaling pathways with pacritinib treatment and evaluation of a Phase 2 trial of treatment with tosedostat in conjunction with cytarabine or decitabine in individuals with AML or myelodysplastic syndrome .Gleevec is considered to become a well tolerated drug, however, side effects do occur, including a variety of skin reactions in around 10 percent of patients, joint effusions, hypopigmentation, renal dysfunction, hepatic dysfunction, anemia and myelosuppression. Related StoriesCornell biomedical engineers develop 'super organic killer cells' to destroy malignancy cells in lymph nodesMD Anderson study reveals why chemotherapy medications not effective for most pancreatic cancers patientsNew antenna-like gadget makes breast cancer surgery easier for surgeonsThe experts from the Memorial Sloan-Kettering Cancer Center in New York say that some sufferers acquiring Gleevec develop hypophosphatemia which inhibits bone formation and resorption, a process known as bone remodelling.

Related Posts

Other Posts From Category "diagnostics":